Abstract
We examined the biological role of p12CDK2-AP1 in cisplatin-mediated responses by using murine ES p12CDK2-AP1 knockout clones generated by a targeted disruption of murine p12CDK2-AP1. Homozygous knockout clones showed an increased cellular proliferation along with an increase in S and a decrease in G2/M phase populations. Interestingly, ES p12CDK2-AP1 knockout clones showed a resistance to cisplatin treatment along with an increased DNA repair activity assessed by host cell reactivation assay using a cisplatin-damaged reporter DNA and a significant reduction of apoptosis upon cisplatin treatment. By using stable p12CDK2-AP1 short interfering RNA (siRNA) clones from human normal oral keratinocytes, we confirmed that downregulation of p12CDK2-AP1 resulted in a resistance to cisplatin. More interestingly, cisplatin treatment resulted in a reduction of CDK2 kinase activity in control clones, but p12CDK2-AP1 knockout clones showed a sustained CDK2 kinase activity. These data suggest that p12CDK2-AP1 plays a role in cisplatin-mediated cellular responses by modulating CDK2 activity. These data further suggest p12CDK2-AP1 is a potential gene therapeutic agent for oral/head and neck cancer in conjunction with DNA-damaging agents such as cisplatin.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D, Christen RD, Boland CR, Koi M, Fishel R and Howell SB . (1996). Cancer Res., 56, 3087–3090.
Agami R and Bernards R . (2000). Cell, 102, 55–66.
Ahn H, Lee E, Kim K and Lee C . (1994). J. Urol., 151, 263–267.
Andreadis C, Vahtsevanos K, Sidiras T, Thomaidis I, Antoniadis K and Mouratidou D . (2003). Oral Oncol., 39, 380–385.
Andrews PA and Howell SB . (1990). Cancer Cells, 2, 35–43.
Andrews PA, Jones JA, Varki NM and Howell SB . (1990). Cancer Commun, 2, 93–100.
Anthoney DA, McIlwrath AJ, Gallagher WM, Edlin AR and Brown R . (1996). Cancer Res., 56, 1374–1381.
Bergoglio V, Canitrot Y, Hogarth L, Minto L, Howell SB, Cazaux C and Hoffmann JS . (2001). Oncogene, 20, 6181–6187.
Boulikas T and Vougiouka M . (2004). Oncol. Rep., 11, 559–595.
Bradford CR, Zhu S, Ogawa H, Ogawa T, Ubell M, Narayan A, Johnson G, Wolf GT, Fisher SG and Carey TE . (2003). Head Neck, 25, 654–661.
Cwikla SJ, Tsuji T, McBride J, Wong DT and Todd R . (2000). J. Oral Maxillofac. Surg., 58, 406–414.
Dedon PC and Borch RF . (1987). Biochem. Pharmacol., 36, 1955–1964.
Derijard B, Hibi M, Wu IH, Barrett T, Su B, Deng T, Karin M and Davis RJ . (1994). Cell, 76, 1025–1037.
Dickson MA, Hahn WC, Ino Y, Ronfard V, Wu JY, Weinberg RA, Louis DN, Li FP and Rheinwald JG . (2000). Mol. Cell. Biol., 20, 1436–1447.
Donze O and Picard D . (2002). Nucleic Acids Res., 30, e46.
Elbashir SM, Lendeckel W and Tuschl T . (2001). Genes Dev, 15, 188–200.
Ferry KV, Hamilton TC and Johnson SW . (2000). Biochem. Pharmacol., 60, 1305–1313.
Fink D, Aebi S and Howell SB . (1998). Clin. Cancer Res., 4, 1–6.
Fishel R and Kolodner RD . (1995). Curr. Opin. Genet. Dev., 5, 382–395.
Fossa SD, Lehne G, Heimdal K and Theodorsen L . (1995). Oncology, 52, 300–305.
Fritsche M, Haessler C and Brandner G . (1993). Oncogene, 8, 307–318.
Gately DP, Sharma A, Christen RD and Howell SB . (1996). Br. J. Cancer, 73, 18–23.
Harrington EA, Bruce JL, Harlow E and Dyson N . (1998). Proc. Natl. Acad. Sci. USA, 95, 11945–11950.
Higuchi E, Oridate N, Furuta Y, Suzuki S, Hatakeyama H, Sawa H, Sunayashiki-Kusuzaki K, Yamazaki K, Inuyama Y and Fukuda S . (2003). Head Neck, 25, 187–193.
Hoffmann TK, Leenen K, Hafner D, Balz V, Gerharz CD, Grund A, Ballo H, Hauser U and Bier H . (2002). Anticancer Drugs, 13, 93–100.
Hu MG, Hu GF, Kim Y, Tsuji T, McBride J, Hinds P and Wong DT . (2004). Cancer Res., 64, 490–499.
Johnson SW, Laub PB, Beesley JS, Ozols RF and Hamilton TC . (1997). Cancer Res., 57, 850–856.
Johnson SW, Perez RP, Godwin AK, Yeung AT, Handel LM, Ozols RF and Hamilton TC . (1994). Biochem. Pharmacol., 47, 689–697.
Karran P and Bignami M . (1994). BioEssays, 16, 833–839.
Kastan MB, Onyekwere O, Sidransky D, Vogelstein B and Craig RW . (1991). Cancer Res., 51, 6304–6311.
Kharbanda S, Ren R, Pandey P, Shafman TD, Feller SM, Weichselbaum RR and Kufe DW . (1995). Nature, 376, 785–788.
Khuri FR, Shin DM, Glisson BS, Lippman SM and Hong WK . (2000). Semin. Oncol., 27, 25–33.
Kim ES and Glisson BS . (2003). Cancer Treat. Res., 114, 295–314.
Kim Y, Tsuji T, Elovic A, Shintani S, Mihara M, Salih E, Kohno Y, Chin BR, Patel V, Wong DTW and Todd R . (2001). Int. J. Oral Biol, December, 87–91.
Knudsen KE, Booth D, Naderi S, Sever-Chroneos Z, Fribourg AF, Hunton IC, Feramisco JR, Wang JY and Knudsen ES . (2000). Mol. Cell. Biol., 20, 7751–7763.
Kohno Y, Patel V, Kim Y, Tsuji T, Chin BR, Sun M, Bruce Donoff R, Kent R, Wong D and Todd R . (2002). Oral. Oncol., 38, 274–280.
Kolodner RD and Marsischky GT . (1999). Curr. Opin. Genet. Dev., 9, 89–96.
Lai GM, Ozols RF, Smyth JF, Young RC and Hamilton TC . (1988). Biochem. Pharmacol., 37, 4597–4600.
Lan Z, Sever-Chroneos Z, Strobeck MW, Park CH, Baskaran R, Edelmann W, Leone G and Knudsen ES . (2002). J. Biol. Chem., 277, 8372–8381.
Leirdal M and Sioud M . (2002). Biochem. Biophys. Res. Commun., 295, 744–748.
Li Q, Yu JJ, Mu C, Yunmbam MK, Slavsky D, Cross CL, Bostick-Bruton F and Reed E . (2000). Anticancer Res., 20, 645–652.
Loehrer PJ and Einhorn LH . (1984). Ann. Intern. Med., 100, 704–713.
Masuda H, Ozols RF, Lai GM, Fojo A, Rothenberg M and Hamilton TC . (1988). Cancer Res., 48, 5713–5716.
Matsuo K, Shintani S, Tsuji T, Nagata E, Lerman M, McBride J, Nakahara Y, Ohyama H, Todd R and Wong DT . (2000). FASEB J., 14, 1318–1324.
Milas L, Mason KA, Liao Z and Ang KK . (2003). Head Neck, 25, 152–167.
Mistry P, Loh SY, Kelland LR and Harrap KR . (1993). Int. J. Cancer, 55, 848–856.
Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B and Reed JC . (1994). Oncogene, 9, 1799–1805.
Miyashita T and Reed JC . (1995). Cell, 80, 293–299.
Mortensen RM, Conner DA, Chao S, Geisterfer-Lowrance AA and Seidman JG . (1992). Mol. Cell. Biol., 12, 2391–2395.
Mukai M, Kanzaki A, Chen ZS, Miyashita H, Sumizawa T, Furukawa T, Haraguchi M, Takebayashi Y, Takamatsu H and Akiyama S . (2002). Oncol. Rep., 9, 839–844.
Offer H, Erez N, Zurer I, Tang X, Milyavsky M, Goldfinger N and Rotter V . (2002). Carcinogenesis, 23, 1025–1032.
Ozols RF . (1992). Curr. Probl. Cancer, 16, 61–126.
Ozols RF and Williams SD . (1989). Curr. Probl. Cancer, 13, 285–335.
Parker RJ, Eastman A, Bostick-Bruton F and Reed E . (1991). J. Clin. Invest., 87, 772–777.
Pendyala L, Velagapudi S, Toth K, Zdanowicz J, Glaves D, Slocum H, Perez R, Huben R, Creaven PJ and Raghavan D . (1997). Clin. Cancer Res., 3, 793–798.
Perez RP . (1998). Eur. J. Cancer, 34, 1535–1542.
Perez RP, Hamilton TC and Ozols RF . (1990). Pharmacol. Ther., 48, 19–27.
Rubin E, Kharbanda S, Gunji H, Weichselbaum R and Kufe D . (1992). Cancer Res., 52, 878–882.
Runger TM, Emmert S, Schadendorf D, Diem C, Epe B and Hellfritsch D . (2000). J. Invest. Dermatol., 114, 34–39.
Shintani S, Mihara M, Terakado N, Nakahara Y, Matsumura T, Kohno Y, Ohyama H, McBride J, Kent R, Todd R, Tsuji T and Wong DT . (2001). Clin. Cancer Res., 7, 2776–2782.
Shintani S, Ohyama H, Zhang X, McBride J, Matsuo K, Tsuji T, Hu MG, Hu G, Kohno Y, Lerman M, Todd R and Wong DT . (2000). Mol. Cell. Biol., 20, 6300–6307.
Song H, Sondak VK, Barber DL, Reid TJ and Lin J . (2004). Int. J. Oncol., 24, 1017–1026.
Todd R, McBride J, Tsuji T, Donoff RB, Nagai M, Chou MY, Chiang T and Wong DT . (1995). FASEB J., 9, 1362–1370.
Tsuji T, Duh FM, Latif F, Popescu NC, Zimonjic DB, McBride J, Matsuo K, Ohyama H, Todd R, Nagata E, Terakado N, Sasaki A, Matsumura T, Lerman MI and Wong DTW . (1998). J. Biol. Chem., 273, 6704–6709.
Tsutsumi T, Kawakami A, Ozawa Y, Kawaguchi H, Fujii H, Sawano T and Asamoto H . (1991). Gan. To Kagaku Ryoho, 18, 1003–1006.
Walker DH, Adami GR, Dold KM and Babiss LE . (1995). Cell. Growth Differ., 6, 1053–1061.
Yuan Z, Sotsky Kent T and Weber TK . (2003). Oncogene, 22, 6304–6310.
Zanke BW, Boudreau K, Rubie E, Winnett E, Tibbles LA, Zon L, Kyriakis J, Liu FF and Woodgett JR . (1996). Curr. Biol., 6, 606–613.
Zhang X, Tsao H, Tsuji T, Minoshima S, McBride J, Majewski P, Todd R, Shimizu N, Wong DT, Housman DE and Haluska FG . (1999). Biochem. Biophys. Res. Commun., 255, 59–63.
Acknowledgements
We thank Dr Marxa Figueiredo for critical reading of this manuscript and Dr Rick Mortensen for providing us with the vector for generating murine ES targeting construct. This work was supported by PHS Grant T32 DE 007296-08 to YK and RO1 DE 14857 to DTW.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kim, Y., McBride, J., Zhang, R. et al. p12CDK2-AP1 mediates DNA damage responses induced by cisplatin. Oncogene 24, 407–418 (2005). https://doi.org/10.1038/sj.onc.1208222
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208222
Keywords
This article is cited by
-
CDK2-AP1 inhibits growth of breast cancer cells by regulating cell cycle and increasing docetaxel sensitivity in vivo and in vitro
Cancer Cell International (2014)